Russian firm to buy troubled Biopure corporation in the US
This article was originally published in Scrip
OPK Biotech, a US subsidiary of the Luxembourg-based OPK Luxadvor owned by Sergei Pugachev, one of Russia's oligarchs, is to acquire the assets of Biopure Corporation, a troubled US biotech company, at a recent bankruptcy court auction in Boston. Biopure filed for chapter 11 bankruptcy protection in the US on July 16th, when its total debt had reached $2.7 million and its assets were worth an estimated $5.1 million.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.